Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Half‐Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand‐Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)

Trial Profile

Half‐Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand‐Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Erythrodysaesthesia
  • Focus Therapeutic Use
  • Acronyms BRIMOCAN
  • Most Recent Events

    • 07 Jan 2019 Status changed from recruiting to discontinued.
    • 21 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top